Alpha-emitter Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors

Sudhir Bhimaniya; Hina Shah; Heather A Jacene

doi:10.1016/j.cpet.2024.03.005

Alpha-emitter Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors

PET Clin. 2024 Jul;19(3):341-349. doi: 10.1016/j.cpet.2024.03.005. Epub 2024 Apr 23.

Authors

Sudhir Bhimaniya¹, Hina Shah², Heather A Jacene²

Affiliations

¹ Harvard Medical School, Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. Electronic address: sbhimaniya@bwh.harvard.edu.
² Harvard Medical School, Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

PMID: 38658229
DOI: 10.1016/j.cpet.2024.03.005

Abstract

Peptide receptor radionuclide therapy (PRRT) has become mainstream therapy of metastatic neuroendocrine tumors not controlled by somatostatin analog therapy. Currently, beta particle-emitting radiopharmaceuticals are the mainstay of PRRT. Alpha particle-emitting radiopharmaceuticals have a theoretic advantage over beta emitters in terms of improved therapeutic efficacy due to higher cancer cell death and lower nontarget tissue radiation-induced adverse events due to shorter path length of alpha particles. We discuss the available evidence for and the role of alpha particle PRRT.

Keywords: Alpha particles; Beta particles; Neuroendocrine tumors; Peptide receptor radiopharmaceutical therapy (PRRT); Somatostatin receptors.

Publication types

Review

MeSH terms

Alpha Particles* / therapeutic use
Humans
Neuroendocrine Tumors* / diagnostic imaging
Neuroendocrine Tumors* / radiotherapy
Octreotide / analogs & derivatives
Octreotide / therapeutic use
Radioisotopes / therapeutic use
Radiopharmaceuticals* / therapeutic use
Receptors, Peptide*

Substances

Radiopharmaceuticals
Receptors, Peptide
Octreotide
Radioisotopes